

Tkaczynski E, Arulsevan A, Tkaczynski J, et al. 2-O, 3-O desulfated heparin mitigates murine chemotherapy- and radiation-induced thrombocytopenia. *Blood Adv.* 2018;2(7):754-761.

On page 760 under “Authorship” in the 10 April 2018 issue, the conflict-of-interest paragraph should have read, “T.P.K. is the original inventor of 2-O, 3-O desulfated heparin. He was the scientific founder and is a current stockholder of Cantex Pharmaceuticals, Inc. The remaining authors declare no competing financial interests.” The error has been corrected in the published article.

---

DOI 10.1182/bloodadvances.2018020461

© 2018 by The American Society of Hematology